Favorable Response to CD34+ Cell Therapy Is Associated with a Decrease of Galectin-3 Levels in Patients with Chronic Heart Failure

Table 1

Baseline patient characteristics. Values are presented as , number of patients (percent), or median (IQR) for NT-proBNP.

	All ()	ICMP ()	DCMP ()
Age (y)				0.16
Male gender (%)	51 (83)	15 (79)	36 (85)	0.54
LVEF (%)				0.41
6MWT (m)				0.92
NT-proBNP (pg/mL (IQR))	1132 (350-2279)	1133 (394-2239)	1127 (333-2359)	0.99
Creatinine (mmol/L)				0.52
Bilirubin (μmol/L)				0.75
Sodium (mmol/L)				0.63
AST (μmol/L)				0.62
AF (μmol/L)				0.39
gGT (μmol/L)				0.10
RDW (%)				0.92
Leukocytes (×109)				0.47
Hemoglobin (g/L)				0.32
Platelet count (×109)				0.27
Medical management
ACEI/ARB	61 (100)	19 (100)	42 (100)	/
Beta blockers	61 (100)	19 (100)	42 (100)	/
MRA	61 (100)	19 (100)	42 (100)	/
Diuretic	33 (54)	12 (63)	21 (51)	0.34
Aspirin	21 (34)	19 (100)	2 (4)	<0.05
Galectin-3 levels (ng/mL)
Baseline				0.12
3 months				0.83

ICMP: ischemic cardiomyopathy; DCMP: nonischemic cardiomyopathy; LVEF: left ventricular ejection fraction; 6MWT: 6-minute walk test; AST: aspartate transaminase; AF: alkaline phosphatase; gGT: γ-glutamyltranspeptidase; RDW: red cell distribution width; ACEI: angiotensin convertase inhibitor; ARB: angiotensin receptor blocker; MRA: mineralocorticoid receptor antagonist.